The stock price of Niagen Bioscience Inc (NASDAQ: NAGE) has dropped by -0.58 compared to previous close of 13.82. Despite this, the company has seen a gain of 2.23% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-24 that NAGE is a leader in the growing NAD+ supplement market, benefiting from rising health and longevity trends and strong brand awareness with its flagship Tru Niagen product. Analyst estimates for 2025 remain too low; further upside revisions look possible based on our alternative data channel checks. Our DCF valuation suggests at least 20% upside as a standalone company, and even more if viewed through the lens of a potential acquirer.
Is It Worth Investing in Niagen Bioscience Inc (NASDAQ: NAGE) Right Now?
Niagen Bioscience Inc (NASDAQ: NAGE) has a price-to-earnings ratio of 79.56x that is above its average ratio. Additionally, the 36-month beta value for NAGE is 2.12. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NAGE is 49.81M and currently, short sellers hold a 6.57% ratio of that float. The average trading volume of NAGE on June 27, 2025 was 879.40K shares.
NAGE’s Market Performance
NAGE’s stock has seen a 2.23% increase for the week, with a 25.14% rise in the past month and a 85.93% gain in the past quarter. The volatility ratio for the week is 5.10%, and the volatility levels for the past 30 days are at 5.19% for Niagen Bioscience Inc. The simple moving average for the past 20 days is 4.38% for NAGE’s stock, with a 99.33% simple moving average for the past 200 days.
Analysts’ Opinion of NAGE
Many brokerage firms have already submitted their reports for NAGE stocks, with Canaccord Genuity repeating the rating for NAGE by listing it as a “Buy.” The predicted price for NAGE in the upcoming period, according to Canaccord Genuity is $13 based on the research report published on May 27, 2025 of the current year 2025.
B. Riley Securities gave a rating of “Neutral” to NAGE, setting the target price at $2.40 in the report published on August 11th of the previous year.
NAGE Trading at 29.74% from the 50-Day Moving Average
After a stumble in the market that brought NAGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.18% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NAGE starting from Lopez Carlos Luis, who purchase 273 shares at the price of $7.86 back on Mar 07 ’25. After this action, Lopez Carlos Luis now owns 2,251 shares of Niagen Bioscience Inc, valued at $2,146 using the latest closing price.
Jaksch Frank L Jr, the Director of Niagen Bioscience Inc, sale 37,161 shares at $6.19 during a trade that took place back on Dec 13 ’24, which means that Jaksch Frank L Jr is holding 244,179 shares at $229,956 based on the most recent closing price.
Stock Fundamentals for NAGE
Current profitability levels for the company are sitting at:
- 0.12 for the present operating margin
- 0.63 for the gross margin
The net margin for Niagen Bioscience Inc stands at 0.13. The total capital return value is set at 0.26. Equity return is now at value 33.47, with 20.83 for asset returns.
Based on Niagen Bioscience Inc (NAGE), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at 4.57.
Currently, EBITDA for the company is 9.21 million with net debt to EBITDA at -2.85. When we switch over and look at the enterprise to sales, we see a ratio of 9.66. The receivables turnover for the company is 13.89for trailing twelve months and the total asset turnover is 1.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.66.
Conclusion
In conclusion, Niagen Bioscience Inc (NAGE) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
